Over the years, the Group has developed a strong connection with the international scientific community.. From the 1960s, Zambon adopted a particularly bold strategy of internationalisation which saw the group's presence grow through settlements not only the largest European countries, but in South America and the Far East. This journey, thanks also to its initiatives in China and India, gave the Zambon Group a privileged position among Europe's leading medium-sized pharmaceuticals companies.
Its story dates back to the late 1800s, when founder Gaetano Zambon graduated in pharmacy before settting up a wholesale warehouse of drugs and basic medicinal ingredients. This led to the opening of a small, local grocery store, selling everything from liquors to insecticides. Five brothers-in-law from the family became progressively involved in the business, each of which had a particular skill. For many years, the family and the business would interweave with one another, creating an osmosis that thrived on shared energies and infectious motivation.
In the thirties the company began manufacturing galenic products. Following the destruction caused by World War Two and the consequent reconstruction, it then moved on to industrial drug production, thanks partly to a sharp rise in research. At the same time, as part of a process of vertical integration, the company started to produce basic chemical substances.
However, it was during the post-war period that the Zambon Group turned its focus to internationalisation and research. Control passed into the hands of Alberto Zambon, who had the ability to carry the company through the golden years of the Italian "economic miracle" with realism and foresight. He transferred the head office from Vicenza to Bresso (Milan), stepped-up research and abandoned the galenic division to focus on industrial producton. He saw the importance - before so many others - of both creating "proprietary" products, deriving from internal research and not manufactured by licence, and of approaching new markets. The fifties saw expansion into Europe and overseas, with the first industrial settlement in Brazil. By the sixties, a molecule that had thus far failed to produce satisfying results in the United States was subject to innovative research and led to the formulation of Fluimucil, which remains one of the group's most successul products, together with Monuril and Spidifen.
Alberto Zambon also knew how to keep close control over the majority shareholding, which otherwise was at risk of dissipation. Today, his sons represent the third generation of an industrial family proud of its 100-year history and that - following the grandfather's teachings - has assumed a directing role, leaving management to the managers. The third generation of the Zambon family are "professional shareholders", who monitor and control the company during important stages and have the competence to understand managerial decisions and to have a decided influence over strategic processes.